Genomics and Personalized Medicine Quotes

“Another example is tamoxifen, which is used for treatment of endocrine responsive breast cancer. Tamoxifen is given to patients postsurgery and dramatically reduces the rate of cancer recurrence. This drug is metabolized by cytochrome P450 2D6, the product of the CYP2D6 gene. Based on their DNA, there are patients with little CYP2D6 activity who are poor metabolizers and others with high activity who are extensive metabolizers. An FDA-approved genetic test exists for finding the variants of the CYP2D6 gene to help guide tamoxifen administration, but the lack of study data demonstrating its role in improving patient outcomes has, to date, led insurance companies to refuse to cover the test. Beyond having ramifications for drug efficacy, genetics also may play a role in the side effects of drugs.”
― Michael Snyder, Genomics and Personalized Medicine: What Everyone Needs to Know®

“In the above examples, a sample of the tumor (e.g., biopsy) is tested to determine the molecular signature. Testing may be by genetic sequence tests (e.g., for BCR-ABL, mutated EGFR, or HER2 gene amplification) or tissue protein stains (e.g., for the presence of ER/PR receptors or HER2 protein overexpression). The results of the testing will guide the choice of treatment—it will be personalized for the individual.”
― Michael Snyder, Genomics and Personalized Medicine: What Everyone Needs to Know®